Considerations on causality in pharmacovigilance.

Area of Science:

• Pharmacovigilance
• Epidemiology
• Causal Inference

Background:

• Causality is a long-standing debate across multiple disciplines.
• Precisely defining causal chains is crucial for strengthening arguments and addressing data limitations.
• Multiple potential causes often exist for a single effect, necessitating contextual probability evaluation.

Purpose of the Study:

• To explore the complexities of establishing causality in pharmacovigilance.
• To highlight the importance of evaluating multiple causal factors and chains.
• To discuss the application of established criteria and epidemiological methods in determining drug-induced adverse effects.

Main Methods:

• Utilizing patient history, clinical findings, and laboratory tests for individual diagnosis.
• Applying the Bradford-Hill criteria for assessing potential causal factors.
• Employing pharmacoepidemiology to determine population incidences and a priori probabilities of causes.

Main Results:

• Individual diagnosis combines various data points to infer pathological causes and their strength.
• Pharmacoepidemiology provides population-level incidence data for competing causes.
• Epidemiological evidence alone cannot exclude drug causation in rare adverse events but can indicate incidence levels.

Conclusions:

• Accurate causal inference in pharmacovigilance demands rigorous evaluation of all contributing factors and chains.
• The Bradford-Hill criteria and pharmacoepidemiology are essential tools for assessing causality.
• Understanding causal inference is critical in legal contexts involving adverse drug reactions.